Amgen's bone drug denosumab won approval for two new indications yesterday, both under the brand name Prolia: to increase bone mass in breast cancer patients on aromatase inhibitor therapy, and for prostate cancer patients undergoing androgen-deprivation therapy. Denosumab is also sold under the brand name Xgeva for reducing fractures and other bone problems in patients with bone metastases from solid tumors. Amgen is studying the drug for other uses, as well.
Eli Lilly said using patient navigators to guide subjects through the treatment process, as well as taking into account language and ethnic considerations of potential participants, can increase minority involvement in clinical trials. In a lung cancer study that began with 19% minority representation, after the interventions were introduced, minority participation among remaining enrollees increased to 43%.